
Natera Investor Relations Material
Latest events

Q1 2025
Natera
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Natera Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Product revenues
Licensing and other revenues
Expenses by
Financials
Natera, Inc. develops and commercializes molecular testing services for reproductive health. It provides Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to analyze chromosomal anomalies or subchromosomal aberrations; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or subchromosomal aberrations; and Anora product platform, a single tube platform to detect cell-free DNA in maternal blood.
Key slides for Natera Inc


Q4 2024
Natera Inc


Q4 2024
Natera Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
NTRA
Country
🇺🇸 United States